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Introduction
Splenic marginal zone lymphoma (SMZL) is a well-defined, 
mature B-cell neoplasm [1] that mostly affects elderly indi-
viduals [2,3]. Although the lymphoma burden mainly affects 
the spleen, nearly all patients are in stage IV at diagnosis, due 
to bone marrow (BM) infiltration. Nearly 50% of cases exhibit 
a subtle leukemic component with a variable percentage of 
villous lymphocytes [4]. Signs and symptoms mainly con-
sist of peripheral cytopenia and/or abdominal discomfort 
caused by splenomegaly. In most cases, SMZL pursues an 
indolent clinical course, and the median overall survival 
(OS) is approximately 10 years [5]. However, in about 20% 
of cases, the neoplasm progresses at a more aggressive pace 
with an OS of less than 5 years [6–8]. Moreover, in around 
10% of cases, histologic transformation occurs toward high-
grade histotypes, such as diffuse large B-cell lymphoma 
(DLBCL) [9–11]. Notably, this unfavorable evolution is not 
prevented by splenectomy [12]. It is widely accepted that 
patients who are asymptomatic at diagnosis should be man-
aged with a watchful eye for progression [3–6,11]. Treatment 
requirements may be indicated by a number of clinical and 
laboratory parameters, including the presence of bulky or 
symptomatic splenomegaly, B-symptoms, autoimmune phe-
nomena or significant cytopenia [13,14]. Diverse treatments, 
including splenectomy, rituximab (R) and chemotherapy 
with or without R, provide effective symptom control and 
recovery from cytopenias, but comparative trials are lacking 
[15]. Recently, a growing number of studies have shown that 
R immunotherapy achieved a high overall response rate 
(ORR) that presented a challenge to the role of palliative sple-
nectomy as first-line therapy [16–18]. In addition, retrospec-
tive studies have suggested that a combined approach of R 
with chemotherapy, particularly purine analogs, could attain 
better results than R alone, in terms of complete response 
(CR) rates and progression-free survival (PFS) [15,19].
Myocet (Cephalon, Frazer, PA) is a liposome-encapsulated 
formulation of doxorubicin. This formulation provides par-
ticular pharmacokinetic properties, which result in a larger 
area under the curve, smaller volume of distribution and 
preferential distribution to the liver, spleen and lymphoid tis-
sues, compared to conventional doxorubicin [20]. Liposomal 
doxorubicin was suggested as a strategy to minimize cardiac 
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side effects and promote selective drug uptake by lymphoma 
cells [21]. Moreover, R in association with cyclophosphamide, 
vincristine, liposomal doxorubicin and prednisone (R-COMP) 
was demonstrated to effectively treat DLBCL in older and/or 
frail patients, with an acceptable toxicity profile [22]. Taken 
together, these characteristics make R-COMP a potentially 
effective candidate for the treatment of SMZL.
Based on the above findings, in 2005 the former Gruppo 
Italiano Studio Linfomi (GISL), current Fondazione Italiana 
Linfomi (FIL), started a prospective multicenter study to 
investigate the activity and toxicity of R-COMP as a first-line 
therapy in a series of patients with SMZL who were either 
ineligible for or unwilling to undergo a splenectomy.
Patients and methods
Study design and objective
This multicenter phase II trial included symptomatic patients 
with SMZL. The primary endpoint was ORR after administra-
tion of R-COMP as first-line treatment. Secondary endpoints 
included safety, CR rate, failure-free survival (FFS), OS and 
risk of histological transformation.
The trial (Italian OsSC number: 2005-000693-45) was 
approved by the ethics committees according to local rules. 
It was compliant with Good Clinical Practice guidelines and 
the October 2008 revision of the Declaration of Helsinki. All 
participants provided written informed consent.
Diagnosis
The diagnosis of SMZL in patients without splenectomy was 
based on the integration of peripheral blood (PB) lympho-
cyte morphology and immunophenotype, bone marrow 
(BM) histology and immunophenotypical analyses [13]. Spe-
cifically, the presence of a mixed nodular and intrasinusoidal 
pattern of infiltration by medium sized lymphoid cells with 
abundant clear cytoplasm with a CD19, CD20, CD5, 
CD10, CD23, CD43, FMC7, CD103, bcl-2, cyclin 
D1  immunophenotype [3] and a “chronic lymphocytic leu-
kemia (CLL) score” of 2 or less were considered as matching 
diagnostic criteria for SMZL and included in the study.
In patients with splenectomy, the diagnosis was based 
on spleen histology according to World Health Organization 
(WHO) criteria [1]. For study inclusion, SMZL was diagnosed 
based on the histological report of the local pathologist. At 
the end of the study, all histological specimens were centrally 
reviewed by the FIL board of expert hematopathologists; any 
cases with unconfirmed SMZL diagnoses were removed from 
the final analysis.
For study eligibility, patients with SMZL had to be older 
than 18 years and show negative hepatitis B surface anti-
gen (HBsAg), anti-human immunodeficiency virus (HIV) 
and anti-hepatitis C virus (HCV) serological analyses, an 
Eastern Cooperative Oncology Group (ECOG) performance 
status  2 and a left ventricular ejection fraction  50%.
The prerequisite for enrollment was that patients required 
treatment but were ineligible for or unwilling to undergo 
splenectomy. The need for treatment was based on the occur-
rence of bulky disease status (defined as  6 cm below the left 
costal margin); a worsening condition; painful splenomegaly 
without conspicuous lymphadenopathy irrespective of con-
current cytopenia; the presence of symptomatic/progressive 
cytopenia (hemoglobin  10 g/dL, platelets  100 000/mm3, 
neutrophils  1000/mm3) due to any cause; or a promi-
nent lymphadenopathy and/or involvement of extranodal 
sites (except for BM and spleen), irrespective of concurrent 
cytopenia.
Splenectomized patients with SMZL were considered eli-
gible when they fulfilled the criteria for requiring treatment 
within 1 year after splenectomy.
Baseline evaluation and treatment
At baseline, after three treatment cycles and at the end of 
treatment, each patient underwent a full history and clini-
cal examination: complete serum biochemistry, including 
lactate dehydrogenase and b2-microglubulin determina-
tions; peripheral blood and BM immunophenotyping; a 
BM biopsy and computed tomography scans of the chest, 
abdomen and pelvis. Cardiac function was evaluated with 
electrocardiography and echocardiography at baseline and 
at the end of treatment.
The R-COMP regimen consisted of 21-day cycles, includ-
ing (day 1) cyclophosphamide 750 mg/m2, vincristine 
1.4 mg/m2 (cap at 2 mg), liposomal doxorubicin 50 mg/m2 
and (days 1–5) prednisone 60 mg/m2, then (day 8 of the first 
cycle and day 1 for subsequent cycles) R 375 mg/m2.
After three cycles, all patients were restaged. Those in 
CR received only one more cycle of R-COMP, patients who 
achieved a partial response (PR) received three more cycles 
of R-COMP and those with no response were withdrawn from 
the study. Dose reductions were not planned. R administra-
tion followed labeling instructions and guidelines. Granu-
locyte-colony stimulating factor (G-CSF) was administered 
according to each institution’s recommendation.
Response criteria
The definition of treatment response followed the revised 
Matutes criteria [13]. Specifically, PR was defined as a 50% or 
greater improvement in SMZL manifestations; this included 
a resolution or decrease in spleen size, improvement of 
cytopenias and resolution or decrease in lymphadenopathy, 
when present. Also, the BM should show a decrease in lym-
phoid infiltration.
CR was defined as the resolution of organomegaly and 
normalization of blood counts (hemoglobin  12 g/dL; 
platelets  100 000/mm3; neutrophils  1500/mm3, with no 
evidence of circulating clonal B cells). Also, little or no BM 
infiltration should be detected with immunohistochemistry.
No response and progressive disease (PD) were defined, 
respectively, as less than 10% improvement and worsening 
of disease manifestations. Follow-up visits were scheduled 
every 3 months until progression or relapse. At the appear-
ance of any signs of progression patients underwent restag-
ing, and when lymphadenopathy occurred lymph nodes 
were biopsied. Thereafter the follow-up visits were scheduled 
according to the center policy or clinical needs.
Survival and toxicity
FFS was measured from the date of study entry to the date of 
any treatment failure, including treatment discontinuation 
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for toxicity, a response less than PR, progression or relapse, 
or to the date of death from any cause. PFS was defined 
as the time of study entry to the time of any documented 
progressive disease, relapse or death from any cause. OS was 
defined as the time of study entry to the last observation or 
death from any cause.
Safety was evaluated by assessing laboratory parameters 
and adverse events. Toxicities were graded with National 
Cancer Institute Common Terminology Criteria for Adverse 
Events (CTCAE version 3.0).
Statistical analysis
The study was planned according to Simon’s optimal two-
stage design [23], with ORR as primary endpoint. In the first 
stage, 19 evaluable patients were enrolled, and with more than 
12 responses observed, 34 additional evaluable patients were 
enrolled in the second stage. Sample size was determined with 
a one-sided test. At a significance of a  0.05 and power of 
90%, we considered ORR rates of 60% and 80% as levels of no 
interest (P0) and of interest (P1), respectively. The study regi-
men would be rejected with fewer than 38 overall responses 
at the final assessment. Given the approximate 10% of patients 
expected to be deemed ineligible after registration for any 
reason, we planned to recruit a total of 60 patients. Data 
were analyzed with the Stata SE/10 package. Time-to-event 
data were analyzed with the Kaplan–Meier method [24] and 
compared with the log-rank test. Results are reported with 
two-sided 95% confidence intervals (CIs). Proportions were 
compared with c2 and Fisher exact tests and a two-sided test 
was used in all tests with a level of significance of 0.05 [25].
Results
Patient characteristics
Between June 2005 and June 2009, 63 patients were prospec-
tively recruited into the study by 21 Italian centers, and 51 
were finally evaluable. Of the 12 patients excluded from the 
final response and survival analysis, one was due to with-
drawal of consent and 11 were due to a revision of the initial 
histologic diagnosis (four nodal marginal zone lymphoma, 
four mantle cell lymphoma [MCL], two non-Hodgkin lym-
phoma [NHL] unspecified and one follicular lymphoma).
The median age at diagnosis was 64 years (range 30–86), 
and 27 (53%) patients were males; nine had undergone a 
splenectomy within 1 year prior to enrollment.
We carried out a post hoc OS analysis according to Inter-
gruppo Italiano Linfomi [7] (IIL) and hemoglobin–platelet– 
lactate dehydrogenase (LDH)–extrahilar lymphadenopathy [26] 
(HPLL) prognostic scores, and 29% and 6% patients were clas-
sified at high risk, respectively. The demographics and baseline 
data of the eligible patients are summarized in Table I.
At the end of the first phase, after analysis of the first 
evaluable 19 patients, an objective response was observed 
in 15 patients (ORR 79%; 95% CI 54–94), higher than the 12 
responses required.
Efficacy
Among the 51 evaluable patients, 41 (80%) completed all six 
cycles of treatment, two (4%) completed treatment after five 
cycles, six (12%) after three cycles and two (4%) after two 
cycles (Figure 1).
Treatment was discontinued due to adverse events (n  2; 
one ictus cerebri and one pneumonitis, after five cycles), 
stable disease (SD) or PD (n  6, after three cycles), infusion 
reaction to liposomal doxorubicin (n  1, after two cycles) 
and death (n  1 sepsis, after two cycles).
The final analysis included 51 patients; among these patients 
an objective response was observed in 43 patients (ORR 84%; 
95% CI 71–93), higher than the 38 responses required to con-
sider the study regimen as active. Responses included 33 CRs 
(65%; 95% CI 50–78) and 10 PRs (20%; 95% CI 10–33) (Table II). 
Among 42 non-splenectomized patients, CR was obtained in 
27 patients (64%; 95% CI 48–78) and PR in nine patients (21%; 
95% CI 10–37), and thus the ORR was 86% (95% CI 71–95). No 
patient achieved a CR within the first three cycles of therapy.
The median follow-up was 68 months (range 2–97). Regard-
ing the definition of FFS, 27 failures were recorded, including 
four treatment discontinuations for toxicity, six responses less 
than PR, 13 relapses or progression after obtaining PR or CR 
and four deaths from causes not related to lymphoma (sec-
ond neoplasia [n  3], splenectomy complication [n  1]). For 
the PFS endpoint, overall 18 patients had progressive disease 
Table I. Patients’ characteristics and active 
disease criteria.
Characteristic (n  51) n %
Male gender 27 53
Age  60 33 65
Performance status  1 2 4
ENS  1 46 90
Hb  12 g/dL 22 43
b2M  UNL* 34 81
Albumin  3.5 g/dL* 6 13
Active disease criteria
 Hb  10 g/dL 12 23
 Plt  100 000/mm3 11 21
 Neutrophils  1000/mm3 3 6
 LDT  12 months 6 12
 LDH  UNL 25 49
 B-symptoms 12 23
 Symptomatic 
splenomegaly
36 71
 Extrasplenic involvement 24 47
 BM involvement  50% 30 59
 Stage IV 51 100
Prognostic scores
 IPI score (n  51) 51
  0–2 11 22
  3 25 49
  4–5 15 29
 IIL score (n  45)
  Low-risk 13 29
  Intermediate-risk 19 42
  High-risk 13 29
 HPLL score (n  51)
  A 24 47
  B 24 47
  C 3 6
 
*Missing values: b2M n  9; albumin n  6.
ENS, extranodal sites including bone marrow 
involvement; Hb, hemoglobin; b2M, b2-microglobulin; 
UNL, upper normal limit; Plt, platelets; LDT, lym-
phocyte doubling time; LDH, lactate dehydrogenase; 
Extrasplenic involvement, lymph nodes with or without 
extranodal sites (excluding BM); BM, bone marrow; IPI, 
International Prognostic Index; IIL, Intergruppo Italiano 
Linfoma [7]; HPLL, hemoglobinplateletLDHlymph 
node extrahilar [26].
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Thus, the median dose intensity for all drugs could be maintained 
up to 90% (median dose intensity, mg/m2: 0.980, 0.977, 0.981, 
0.938 and 0.982 for cyclophosphamide, vincristine, liposome-
encapsulated doxorubicin, prednisone and R, respectively). 
Thirteen (26%) of patients developed severe (grade  3) neutro-
penia and four (8%) developed severe infections (grade  3). Of 
these, two patients died during treatment (sepsis after the sec-
ond cycle and pneumonia after the third cycle) and two went off 
study (one after the third cycle for pseudomonas sepsis and one 
after the fifth cycle for pneumonia).
Non-hematological grade  3 toxicity occurred in four 
cases (8%) (one ictus cerebri; one R allergic reaction; one 
liposomal doxorubicin allergic reaction; one intestinal 
occlusion). Second malignancies occurred in eight cases 
(15%) (three myelodysplastic syndrome [MDS], one bladder 
cancer, one prostate cancer, one melanoma, one Hodgkin 
(three at the end of therapy and 15 during follow-up), and five 
patients died. Overall, 15 deaths were recorded in the study 
population. The estimated 6-year FFS, PFS and OS rates were 
50% (95% CI 36–63), 54% (95% CI 40–67) and 72% (95% CI 
58–83), respectively (Table II and Figure 2).
In the post hoc OS analysis with the two prognostic sys-
tems available, the HPLL score effectively identified patients 
at different risk levels (log-rank test, p  0.026), but the IIL 
score did not show strong prognostic power (log-rank test, 
p  0.471) (Figure 3). Notably, during the median follow-up 
time of 68 months (range 40–97) for surviving patients, no 
case of histological progression to DLBCL was observed.
Toxicity
The observed R-COMP toxicity was substantial but manageable, 
and mostly restricted to neutropenia (Table III and Figure 4). 
Figure 1. Flow chart of the present study, according to the Consolidated Standards of Reporting Trials (CONSORT) statement. PD, progressive 
disease; SD, stable disease; PR, partial response; CR, complete response.
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lymphoma and one MCL); one MDS subsequently evolved 
to full-blown acute myeloid leukemia. The median time 
between the end of treatment and the diagnosis of second 
malignancy was 51 months (range 23–85).
Causes of death
At the time of the analysis, 15 patients had died. The deaths 
were due to disease progression (n  6, 40%), infection 
(n  4, 26%; two in the course of R-COMP and two during 
rescue treatment after progression), second malignancy 
(n  4, 27%) and splenectomy complication (n  1, 7%). All 
deaths, excepted two, were recorded after the completion of 
R-COMP treatment.
Discussion
This trial showed that R-COMP was an effective first-line treatment 
for patients with symptomatic SMZL who had not received sple-
nectomy. The ORR and CR rates were 84% and 65%, respectively.
The observed toxicity is worth highlighting, but it proved 
to be manageable. Indeed, the treatment was discontinued 
owing to toxicity in four patients and deaths related to treat-
ment were recorded in two of these patients. In previous 
phase II trials in elderly patients with NHL, neutropenia 
and infections were the most common toxicities [22,27,28]. 
Accordingly, in the present study, neutropenia was the most 
common (26%) grade  3 toxicity, and severe infections 
accounted for 8% of cases. The median dose intensity was 
greater than 90% for all associated drugs; however, we have 
no data on the use of G-CSF, which was left to the clinician’s 
judgement.
Most deaths in this study were due to causes indirectly 
related to the lymphoma: 27% were due to second malig-
nancy and 27% were due to infections, two that developed in 
the course of R-COMP therapy and two during salvage treat-
ment for relapsed or progressive disease.
The mortality rate may appear high for a rather indolent 
disease such as SMZL; nevertheless the inclusion criteria 
required the presence of symptomatic disease, and more than 
one-third of the enrolled cases had a high International Prog-
nostic Index (IPI) and IIL score [7]. Notably, the 6-year OS of 
this series compares favorably to that reported in a large series 
of patients treated with chemotherapy  Mabthera [19].
Figure 2. Kaplan–Meier analysis of the probability of (a) overall survival (OS), (b) progression-free survival (PFS) and (c) failure-free survival (FFS).
Figure 3. Overall survival stratified by HPLL score.
Table II. Treatment results (n  51).
n % 95% CI
Response to 
chemotherapy
 CR 33 65 50–78
 PR 10 20 10–33
 ORR 43 84 71–93
 SD 3 6
 PD 3 6
 EW 2 3
6-Year survival
 OS 72.5 58.0–82.7
 PFS 54.3 39.6–66.9
 FFS 50.5 36.0–63.3
 CR, complete response; PR, partial response; ORR, 
overall response rate; SD, stable disease; PD, progres-
sive disease; EW, early withdrawal; OS, overall sur-
vival; PFS, progression-free survival; FFS, failure-free 
survival; CI, confidence interval.
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however, data were scarce on the efficacy of systemic therapy. 
Subsequently, some small retrospective studies suggested 
that R monotherapy was very effective and could safely 
replace a splenectomy as the first-line treatment [16–18,30]. 
In these series, the reported OR and CR rates after R mono-
therapy were 88–100% and 31–45%, respectively. However, 
R monotherapy achieved CR in only 35% of treatment-naive 
patients without splenectomy, despite the CR in almost all 
patients with splenectomy. These results suggested that R 
had limited efficacy in clearing the lymphomatous burden 
provided by the spleen reservoir, and/or that the splenic envi-
ronment provided resistance to the established clone. The PFS 
rate in a retrospective analysis of a large series of consecutive 
patients with a long follow-up was 75% at 5 years, which is 
better than that we obtained in the present study with a more 
aggressive and toxic treatment; however, it is worth noting, 
that, after four weekly doses for induction, a maintenance R 
dose was administered every 2 months for up to 2 years, and 
that any comparison of prospective with retrospective studies 
should be viewed cautiously. In patients without splenectomy, 
even better results were reported for R associated with chemo-
therapy, mostly purine analogs. The CR rates were 62–79%, 
and the PFS was 80% at 5 years [19,31]. However, it is difficult 
to make comparisons with retrospective monocentric studies.
Most retrospective series that evaluated SMZL treatment 
had a potentially severe flaw, apart from the selection bias: 
they usually lacked homogeneous criteria for starting treat-
ment, which made comparisons problematic. Furthermore, 
particularly among patients who had not been splenecto-
mized, without a central histological review, it is difficult 
to rule out the possibility that some patients with diverse 
diseases were included [32].
The results of the present study in patients with symptomatic 
SMZL without splenectomy and a median observation time of 
68 months showed high levels of CR (64%), PFS (54%) and OS 
(72%) at 6 years, compared with results from other studies on 
chemoimmunotherapy. Thus, we demonstrated the efficacy 
and safety of a new chemoimmunotherapy protocol for SMZL.
Regarding long-term toxicity, the overall incidence of 
second malignancies was markedly high (15% at 5 years). 
Previous studies reported a high frequency of additional 
cancers in patients with SMZL [8,9,11]. A multicenter, retro-
spective analysis on patients largely treated with systemic 
purine analogs reported 12 secondary cancers and a 5-year 
cumulative incidence rate of 18.3%; moreover, the incidences 
of urinary and lung malignancies were significantly higher 
than those expected [29].
A recent, large monocentric retrospective analysis of 
100 patients who underwent splenectomy with a median follow-
up of 5.15 years reported an 11% incidence of transformation to 
high grade NHL and two deaths secondary to epithelial cancer 
(one hepatocarcinoma and one lung cancer). The overall inci-
dence of secondary neoplasia was 13% [12]. However, it was not 
clear whether other non-fatal neoplasia were recorded.
We would emphasize that, in the present study, we 
recorded three cases of secondary MDS, but no cases of his-
tological transformation toward high-grade lymphoma (i.e. 
DLBCL). In the literature, the reported rates of DLBCL sec-
ondary to SMZL range between 10 and 19% with a median 
time to transformation of around 2 years [10,12]. Conversely, 
no cases of secondary MDS have been reported to date.
When this study was designed, splenectomy was con-
sidered the preferred first-line treatment for SMZL, based 
on heterogeneous historical series, which mostly included 
patients who were splenectomized for diagnostic purposes; 
Figure 4. Distribution of hematological toxicities (CTCAE version 3.0 grade) by cycles of treatment.
Table III. Hematologic toxicities, NCI CTCAE criteria.
Grade
Anemia Neutropenia Thrombocytopenia Infections
n % n % n % n %
0 32 62 29 57 39 76 40 78
1 14 27 6 12 5 10 3 6
2 5 10 3 6 7 14 4 8
3 7 14 2 4
4 6 12 2 4
Total 51 51 51 51
 NCI CTCAE, National Cancer Institute Common Terminology Criteria for 
 Adverse Events.
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A major novelty of this phase II study was the diagnos-
tic approach adopted, which did not include a diagnostic 
splenectomy [14]. Indeed, in all cases, the SMZL diagnosis 
was based on the integration of PB and BM morphology, and 
phenotype. The consistency of these diagnoses was verified 
ad interim by a board of expert hematopathologists, who 
reported 81% concordance. Thus, despite the multicenter 
design of the protocol, the data confirmed that an integrated 
diagnostic approach is suitable for prospective trials investi-
gating a first-line therapy.
In conclusion, R-COMP could be considered an effective 
therapeutic alternative for SMZL, when an association with 
chemoimmunotherapy is considered. The toxicity was sub-
stantial, and certainly higher than that of R monotherapy. 
The occurrence of MDS should be monitored. Although 
R-COMP achieved higher PFS than R monotherapy, at pres-
ent, in our opinion, R-COMP treatment is most suited to 
patients with SMZL symptoms that have a documented or 
possible histological transformation toward a more aggres-
sive histotype due to widespread involvement of abdominal 
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ting as the present study, but with the aim of exploring the 
efficacy and toxicity of bendamustine combined with R.
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